• Clinical Data Visualizations at BMS Merge Trial and Real-World Data

    Bio-IT World | The probability of success is low in early drug discovery and gets progressively more expensive on the journey to marketing approval by the Food and Drug Administration (FDA). To “fail early and fail often” has thus become the mantra of medicine developers needing to direct resources to the candidates most likely to triumph, says Philip Ross, director of translational bioinformatics data science at Bristol-Myers Squibb (BMS). Only 9.6% of drugs that make it to phase I trials ever get FDA approved.

    Oct 26, 2020
  • ‘High-Risk, High-Reward’ Approach To Finding Alzheimer’s Disease Treatments

    Bio-IT World The quest to find new medicines for Alzheimer’s disease (AD) may finally make some headway, thanks to a Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) project that is taking a “high-risk, high-reward” approach to diversifying the drug development pipeline, according to Lara Mangravite, president of Sage Bionetworks. The Seattle-based nonprofit is partnered with Emory University and the Structural Genomics Consortium (SGC) on the initiative.

    Oct 19, 2020
  • FOXP3 Protein Inhibited, Blocking Factor D Protein May Prevent Inflammatory Response, App Crowdsources Drug Candidates: COVID-19 Updates

    Bio-IT World I Cloud-based tool, IDseq, allows tracking of emerging pathogens, scientist who discovered SARS captures detailed look of immune system response to COVID-19, SARS-CoV-2 may become endemic, ORF3B identified as viral factor that impairs immune response, age is an independent factor to virus susceptibility, group of 80 researchers warns against herd immunity approach, high dose favipiravir had significant effect on preventing and treating virus in hamster model, REGN-COV2 antibody ‘cocktail’ offers protection in pre-clinical trial on macaques. Plus: SARS-CoV antibodies effectively neutralize SARS-CoV-2 infection in cultured cells, international open access database aims to reduce duplication of ongoing COVID-19 research and more.

    Oct 15, 2020
  • Proving The Value Of Preventive Genomics

    Bio-IT World | The Bio-IT World Conference & Expo closed out with a plenary keynote presentation on preventive genomics by Robert Green, M.D., professor of medicine at Harvard Medical School and a physician-scientist who directs the G2P Research Program at Brigham and Women’s Hospital and the Broad Institute. Data-sharing difficulties were a recurring theme at this year’s conference but, as the COVID-19 Host Genetics Initiative has demonstrated, it is possible to combine genomic data to rapidly explore markers of disease, he says.

    Oct 14, 2020